Aldeyra to Participate in Citi’s 15th Annual BioPharma Virtual Conference
September 03 2020 - 8:00AM
Business Wire
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today
announced that President and Chief Executive Officer Todd C. Brady,
M.D., Ph.D., will participate in an ophthalmology panel discussion
during Citi’s 15th Annual BioPharma Virtual Conference, taking
place September 8-11, 2020. In addition, Aldeyra’s senior
management will host one-on-one meetings at the conference.
Panel Details
Title: Seeing 20/20 in 2020 Date: Thursday,
September 10, 2020 Time: 9:50 a.m. ET
A live webcast of the panel discussion will be available on the
investor relations page of the company’s corporate website at
https://ir.aldeyra.com. After the live webcast, the event will
remain archived on the Aldeyra Therapeutics website for 90
days.
About Aldeyra Therapeutics
Aldeyra Therapeutics is a clinical-stage biotechnology company
focused on the development of novel therapies with the potential to
improve the lives of patients with immune-mediated diseases. Two of
the company’s lead compounds, reproxalap and ADX-629, target
reactive aldehyde species (RASP), which are elevated in ocular and
systemic inflammatory disease and result in cytokine release via
activation of a broad array of inflammatory factors, including
NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being
evaluated in Phase 3 clinical trials in patients with dry eye
disease and allergic conjunctivitis. The company’s clinical
pipeline also includes ADX-2191, a dihydrofolate reductase
inhibitor in Phase 3 testing for proliferative vitreoretinopathy,
and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19
and ovarian cancer. For more information, visit
https://www.aldeyra.com/ and follow us on LinkedIn, Facebook, and
Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200903005190/en/
Corporate Contact: David McMullin Aldeyra Therapeutics,
Inc. Tel: 781-761-4904 ext. 218 dmcmullin@aldeyra.com
Investor & Media Contact: Scott Solomon Sharon
Merrill Associates, Inc. Tel: 617-542-5300
ALDX@investorrelations.com
Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From Apr 2023 to Apr 2024
